Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Biocryst Pharmaceuticals Showing Market Leadership Earns 85 RS Rating

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Biocryst Pharmaceuticals now clears that threshold, with a jump from 72 to 85 Thursday.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.

Decades of market research reveals that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves.

Looking For Winning Stocks? Try This Simple Routine

Biocryst Pharmaceuticals is not currently offering a proper buying opportunity.  With earnings just released, let's see if the stock goes on to build a base that could launch a new move.

The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 30%. Revenue rose from 31% to 85%.

The company earns the No. 138 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.